HUTCHMED (China) (HCM) Total Current Liabilities (2015 - 2026)
HUTCHMED (China) (HCM) posted quarterly Total Current Liabilities of $275.2 million for Q2 2026, down 19.61% year-over-year from $342.3 million in Q2 2025, and down 12.85% quarter-over-quarter from $315.8 million in Q4 2025.
HUTCHMED (China) (HCM) Total Current Liabilities (2015 - 2026) Analysis & Trends
HUTCHMED (China) (HCM) has reported Total Current Liabilities for 12 consecutive years, with $275.2 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Total Current Liabilities fell 19.61% year-over-year to $275.2 million; the TTM figure through Jun 2026 stood at $275.2 million (down 19.61% YoY), while the FY2025 annual figure was $315.8 million, changed N/A from the prior year.
- Total Current Liabilities declined to $275.2 million in Q2 2026 per HCM's latest filing, from $315.8 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $373.3 million in Q2 2024 and bottomed at $275.2 million in Q2 2026.
- Historically, Total Current Liabilities has averaged $331.9 million across 5 years, with a median of $340.9 million in 2023.
- Annual changes were most pronounced in 2022 — Total Current Liabilities advanced 29.93% — and 2026, when it declined 19.61%.
- HUTCHMED (China)'s Total Current Liabilities stood at $353.9 million in 2022, then declined by 3.68% to $340.9 million in 2023, then climbed by 9.51% to $373.3 million in 2024, then retreated by 15.41% to $315.8 million in 2025, then declined by 12.85% to $275.2 million in 2026.
- Business Quant data shows HCM's Total Current Liabilities at $275.2 million in Q2 2026, $315.8 million in Q4 2025, and $342.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 1.79 Bn |
| 10 | HUTCHMED (China) | 2.18 Bn | 2.18 Bn | - | 275.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 275.21 Mn |
| Dec 31, 2025 | 315.78 Mn |
| Jun 30, 2025 | 342.35 Mn |
| Jun 30, 2024 | 373.29 Mn |
| Jun 30, 2023 | 340.86 Mn |
| Dec 31, 2022 | 353.90 Mn |
| Jun 30, 2022 | 321.86 Mn |
| Dec 31, 2021 | 311.66 Mn |
| Jun 30, 2021 | 247.72 Mn |
| Mar 31, 2021 | 188.52 Mn |
| Dec 31, 2020 | 158.40 Mn |
| Jun 30, 2020 | 119.39 Mn |
| Dec 31, 2019 | 113.10 Mn |
| Sep 30, 2019 | 105.35 Mn |
| Jun 30, 2019 | 110.61 Mn |
| Mar 31, 2019 | 101.33 Mn |
| Dec 31, 2018 | 85.48 Mn |
| Jun 30, 2018 | 84.58 Mn |
| Dec 31, 2017 | 104.60 Mn |
| Jun 30, 2017 | 96.84 Mn |